|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| SEC Form 3 |  |  |  |  |  |  |
| **FORM 3** | **UNITED STATES SECURITIES AND EXCHANGE** |  |  |  |  |  |
|  | **COMMISSION** |  |  | |  |  |
|  |  |  | |  |  |
|  |  | OMB APPROVAL | | |  |
|  | Washington, D.C. 20549 |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  | OMB Number: | 3235- |  |  |
|  |  |  |  |  |
|  | **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** |  | 0104 |  |  |
|  |  |  |  |  |
|  |  | Estimated average burden | | |  |
|  | **SECURITIES** |  |  | 0.5 |  |  |




hours per

response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940



|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Name and Address of Reporting Person | | | | | \* | 2. Date of Event |  |
|  | Requiring Statement |  |
|  | [FINCK BARBARA K](http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001242116) | | | |  |  |
|  |  | (Month/Day/Year) |  |
|  |  |  |  |  |  | 03/16/2022 |  |
|  | (Last) | (First) | (Middle) | |  |  |  |
|  | C/O FORTE BIOSCIENCES, INC. | | | |  |  |  |

3060 PEGASUS PARK DR.,

BUILDING 6

|  |  |
| --- | --- |
| (Street) |  |
| DALLAS TX | 75247 |

3. Issuer Name **and** Ticker or Trading Symbol

[Forte Biosciences, Inc.](http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001419041) [ FBRX ]

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 4. Relationship of Reporting Person(s) to | | 5. | If Amendment, Date of Original | |  |
| Issuer |  | Filed (Month/Day/Year) | | |  |
| (Check all applicable) |  |  |  |  |  |
| X Director | 10% Owner |  |  |  |  |
| 6. | Individual or Joint/Group Filing | |  |
| Officer (give | Other (specify |  |
| (Check Applicable Line) | | |  |
| title below) | below) |  | X | Form filed by One Reporting |  |
|  |  |  |  |
|  |  |  |  | Person |  |

Form filed by More than One

Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Beneficially Owned**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **1. Title of Security (Instr. 4)** | **2. Amount of Securities** | **3. Ownership** | **4. Nature of Indirect Beneficial** | |
|  |  | **Beneficially Owned (Instr.** | **Form: Direct** | **Ownership (Instr. 5)** | |
|  |  | **4)** | **(D) or Indirect** |  |  |
|  |  |  | **(I) (Instr. 5)** |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**Table II - Derivative Securities Beneficially Owned**

**(e.g., puts, calls, warrants, options, convertible securities)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1. Title of Derivative Security (Instr. 4)** | **2. Date Exercisable and** | | **3. Title and Amount of Securities** | | **4.** | **5.** | **6. Nature of** |  |
|  | **Expiration Date** | | **Underlying Derivative Security** | | **Conversion** | **Ownership** | **Indirect Beneficial** |  |
|  | **(Month/Day/Year)** | | **(Instr. 4)** |  | **or Exercise** | **Form:** | **Ownership (Instr.** |  |
|  |  |  |  |  | **Price of** | **Direct (D)** | **5)** |  |
|  |  |  |  | **Amount** |  |
|  |  |  |  | **Derivative** | **or Indirect** |  |  |
|  |  |  |  | **or** | **Security** | **(I) (Instr. 5)** |  |  |
|  |  |  |  | **Number** |  |  |  |  |
|  | **Date** | **Expiration** |  | **of** |  |  |  |  |
|  | **Exercisable** | **Date** | **Title** | **Shares** |  |  |  |  |

**Explanation of Responses:**

**Remarks:**

**No securities are beneficially owned.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | /s/ Paul A. Wagner, Ph.D., | |  | 03/18/2022 |  |
|  | as Attorney-in-Fact |  | |  |
|  |  |  |
|  | \*\* Signature of Reporting | | | Date |  |
|  | Person | | |  |
|  |  |  |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | | | |  |  |
| \* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v). | | | |  |  |

* Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Forte Biosciences, Inc. (the "Company"), hereby constitutes and appoints Paul A. Wagner, Antony Riley, Daniel Koeppen, Benjamin Capps and Thomas Hornish the undersigned's true and lawful attorneys-in-fact to:

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of March, 2022.

Signature: /s/ Barbara K. Finck

Print Name: Barbara K. Finck